Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

BACKGROUND AND RATIONALE:

Transcranial electrical stimulation (tES) represents a promising non-invasive approach for treating Parkinson's disease motor symptoms. The Sphere V3.0 device utilizes amplitude-modulated transcranial pulsed random noise stimulation (am-tPRNS) with randomized timing parameters to target motor cortex regions. Previous clinical experience with this technology includes over 250 participants across multiple studies with over 30,000 hours of treatment data and no adverse events recorded.

VIRTUAL STUDY DESIGN:

This fully remote study leverages HIPAA-compliant telehealth platforms to conduct all assessments and monitoring virtually. Participants receive the device via mail with comprehensive training materials and video tutorials. Virtual onboarding includes supervised device setup and electrode placement training via video call.

DEVICE SPECIFICATIONS:

The Sphere V3.0 employs a 4-electrode array configuration with 3D-printed dry electrodes and dual-channel programmability. Stimulation parameters include pulse duration of 450-650ms (randomly varied), inter-pulse intervals of 45-65ms, phase durations of 4.5-5.5 seconds, and current intensity up to 4mA maximum. Safety features include current limiting circuitry, automatic shutoff if skin contact is compromised, and biocompatible electrode materials.

COMPUTER VISION ANALYSIS:

Dual video protocols collect standardized movement assessments for objective analysis. Protocol A focuses on computer vision analysis with specific camera positioning for tremor (top-down view with white tablecloth) and gait assessment (perpendicular and end-on camera angles). Protocol B provides standard clinical videos for potential future MDS-UPDRS scoring. All videos are collected at consistent times, preferably before 9 AM.

SAFETY MONITORING:

Comprehensive remote safety monitoring includes weekly digital diary submissions, 24/7 emergency hotline support, and predefined escalation pathways. Level 1 events (mild headache, slight skin irritation) are documented in daily diaries. Level 2 events (persistent symptoms) require immediate hotline contact. Level 3 events (severe symptoms) mandate device cessation and emergency medical evaluation.

DATA COLLECTION SYSTEMS:

All data is collected through encrypted, HIPAA-compliant electronic data capture systems with secure cloud-based storage. Device usage metrics are transmitted in real-time to study coordinators. Video uploads utilize automated processing for standardized analysis.

REGULATORY CLASSIFICATION:

This study operates under Non-Significant Risk (NSR) device classification, providing expedited regulatory pathway while maintaining full IRB oversight and FDA compliance standards.

Inclusion criteria

• Adults 18-80 years with confirmed diagnosis of Parkinson's Disease
• Hoehn & Yahr stages 1-4
• Stable medication regimen for 4+ weeks prior to enrollment
• Reliable internet access and telehealth capability
• Ability to provide informed consent
• Willingness to comply with treatment protocols and follow-up procedures

Exclusion criteria

• Metallic head/neck implants (excluding dental fillings)
• Pregnancy or nursing status
• Severe skin conditions at electrode placement sites
• History of epilepsy or seizures (unless technology specifically indicated)
• Recent stroke or traumatic brain injury (within 6 months)
• Severe cognitive impairment preventing treatment understanding
• Any neurological disorders contraindicating transcranial electrical stimulation
• Current participation in other clinical trials
• Inability to commit to full treatment and follow-up schedule